Responder Characteristics Elusive

Valcyte-300x212A team led by Dr. Jose Montoya at Stanford University published results of a chart review of 61 CFS patients treated with Valcyte to identify differences between the 32 “responders” and 19 “nonresponders.” No significant differences were found in the baseline antibody titres to HHV-6 or EBV or other variables analyzed. Longer treatment correlated with an improved response as judged by patient’s self-reported physical and cognitive functioning. (Journal of Medical Virology, Oct. 10, 2012)

Tags: , October 10, 2012